Oooo lemme double check what osscon stuff I’m already on the hook for but this looks rad
June 20, 2025 at 3:39 AM
Oooo lemme double check what osscon stuff I’m already on the hook for but this looks rad
just finished a couple of prototypes for a conference at CSU Fullerton this weekend, OSSCON. You'll have to show up to see the heads side!
Oh and I'll be doing a talk on and demo with the IoT weather station me and a peer reversed!
Oh and I'll be doing a talk on and demo with the IoT weather station me and a peer reversed!
December 3, 2024 at 4:07 AM
just finished a couple of prototypes for a conference at CSU Fullerton this weekend, OSSCON. You'll have to show up to see the heads side!
Oh and I'll be doing a talk on and demo with the IoT weather station me and a peer reversed!
Oh and I'll be doing a talk on and demo with the IoT weather station me and a peer reversed!
#osscon thank you so much go having me and @cyberdave.bsky.social! It was so much fun to meet all the next gen mashers ald share our experiences!
December 7, 2024 at 7:57 AM
#osscon thank you so much go having me and @cyberdave.bsky.social! It was so much fun to meet all the next gen mashers ald share our experiences!
#osscon thank you so much go having me and @cyberdave.bsky.social! It was so much fun to meet all the next gen hackers ald share our experiences!
December 7, 2024 at 7:41 AM
#osscon thank you so much go having me and @cyberdave.bsky.social! It was so much fun to meet all the next gen hackers ald share our experiences!
Limertinib Tablets 80 mg × 20 – by Osscon Pharma | Research Use Only (3rd‑Gen EGFR‑TKI)
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR‑TKI) at 80 mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it…
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR‑TKI) at 80 mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it…
Limertinib Tablets 80 mg × 20 – by Osscon Pharma | Research Use Only (3rd‑Gen EGFR‑TKI)
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR‑TKI) at 80 mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M‑mutated non‑small cell lung cancer, including patients with brain metastases.⚠️ For research use only – Not for human consumption or therapeutic use.
arizona-mall.com
June 13, 2025 at 11:29 AM
Limertinib Tablets 80 mg × 20 – by Osscon Pharma | Research Use Only (3rd‑Gen EGFR‑TKI)
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR‑TKI) at 80 mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it…
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR‑TKI) at 80 mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it…